| Ytd | 23.23% | |
| 1y | 49.44% |
| Open | 123.97 | Prev Close | 123.94 | Low | 123.95 | High | 123.99 | Mkt Cap | 9.13B |
| Vol | 0.00 | Avg Vol | 2.33M | EPS | -5.69 | P/E | -21.79 | Forward P/E | -29.99 |
| Beta | 1.14 | Short Ratio | 0.56 | Inst. Own | 113.30% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 112.22 | 200-d Avg | 103.43 | 1yr Est | 124.00 |
Fifth Third Bancorp bought a new position in shares of Nuvalent, Inc. (NASDAQ: NUVL) during the firs
BALA CYNWYD, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the followi
BALA CYNWYD, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the followi
Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, includi
Top Wall Street analysts changed outlook on top names. View all changes on analyst ratings page. See
Bernstein analyst Jeffrey Walch downgrades Nuvalent (NASDAQ:NUVL) from Outperform to Market Perfo
During market turbulence, investors turn to dividend-yielding stocks. Benzinga offers latest analyst
Top analysts changed outlook on top names, including downgrades, upgrades, and initiations. Check ou
The Nasdaq 100 sank 3.3% Tuesday as AI and optical stocks cratered, while cash rotated into real est
US stocks down, Dow Jones drops 300 points. Real estate shares up, technology stocks down. U.S. trad
US stocks higher, Dow Jones index up 300 points on strong earnings and sales guidance from J.M. Smuc
Top Wall Street analysts changed outlook on top names. See all changes on analyst ratings page. Anal
GSK will acquire Nuvalent for $10.6 billion to expand its lung cancer pipeline as Nuvalent shares su
GSK to acquire Nuvalent for $10.6 billion, shares rise 38.2%. Other gainers include CCTG, CHAI, RGNT
Multi-product oncology deal for assets that have validated targets and aim to address efficacy and/o
During Thursday, 849 stocks hit new 52-week lows.
On Friday, 431 companies hit new 52-week lows.